Mild acne may be initially treated with this first line agent:

Recurrent urinary tract infections (UTIs) with systemic symptoms suggest a more complicated infection, possibly involving upper urinary tract involvement such as pyelonephritis or resistant organisms. Treatment selection must consider local antimicrobial resistance patterns, severity of symptoms, and prior antibiotic exposure. Broader-spectrum antibiotics are often required when resistance is a concern or when infection is not limited to the lower urinary tract. Therapy duration is also extended in more complex presentations.

Rationale:
A. Ciprofloxacin (Cipro) is an appropriate option in this scenario because it provides broad-spectrum coverage against common urinary pathogens and achieves good tissue penetration, including renal tissue. In a patient with recurrent UTI and systemic symptoms, there is concern for resistant organisms or upper tract involvement, making fluoroquinolones a reasonable choice when resistance patterns support their use. A 7-day course is consistent with treatment for complicated infection.

B. Trimethoprim-sulfamethoxazole (Bactrim) is typically used for uncomplicated cystitis with a short 3-day course when local resistance rates are low. However, in recurrent infections with systemic symptoms and concern for resistance, it may be ineffective due to increasing E. coliresistance. It is not the best empiric choice in this higher-risk presentation.

C. Clarithromycin (Biaxin) is not appropriate for urinary tract infections because it has poor activity against common uropathogens such as E. coli. Macrolides are primarily used for respiratory and certain atypical infections, not urinary tract infections. Therefore, it would not provide adequate empiric coverage in this case.

D. Fosfomycin (Monurol) is used as a single-dose therapy for uncomplicated lower urinary tract infections. It is not appropriate for recurrent UTIs with systemic symptoms or suspected upper urinary tract involvement. Its limited systemic penetration makes it unsuitable for more complicated or resistant infections.

Lithium is a narrow therapeutic index medication commonly used for bipolar disorder to stabilize mood and prevent manic and depressive episodes. Because the difference between therapeutic and toxic levels is small, patients require careful monitoring of serum levels, renal function, and clinical symptoms. Toxicity can develop gradually or suddenly and may be triggered by dehydration, drug interactions, or impaired renal clearance. Early recognition of toxicity signs is critical to prevent serious neurologic and systemic complications.

Rationale:
A. A new or worsening tremor is an early sign of lithium toxicity. With Lithium, mild fine tremors may occur at therapeutic levels, but progression to coarse tremors suggests increasing serum concentration and potential toxicity. This symptom reflects early neuromuscular involvement and requires prompt evaluation of serum lithium levels.

B. Nausea and vomiting are common gastrointestinal manifestations of lithium toxicity. As serum levels of Lithium rise, GI irritation occurs early and may precede more severe neurologic symptoms. These symptoms should not be dismissed as routine side effects when they are persistent or worsening.

C. Confusion is a serious neurologic sign of lithium toxicity indicating central nervous system involvement. Elevated levels of Lithium can impair cognitive function, leading to disorientation, lethargy, and in severe cases, seizures or coma. This is a late and potentially life-threatening manifestation requiring urgent intervention.

D. All options are correct because tremor, nausea/vomiting, and confusion are all recognized clinical signs of lithium toxicity. With Lithium, toxicity affects multiple body systems including gastrointestinal, neurologic, and neuromuscular systems. Recognizing the full spectrum of symptoms is essential for early detection and prevention of severe complications.